In a recent SEC filing, John A. Borgeson, Chief Financial Officer of Kodiak Sciences Inc., disclosed a series of stock transactions that took place on October 21, 2026. This activity is significant as it reflects the financial maneuvers of a key executive within the company.
Kodiak Sciences Inc. operates in the biological products sector, focusing on innovative solutions in life sciences. The company is incorporated in Delaware and is publicly traded under the ticker symbol KOD. Its most recent filings include a Form 4 submitted on October 23, 2026, and a Form 144 filed just two days prior, on October 21, 2026.
The filing reveals that Borgeson acquired 30,000 shares of Kodiak common stock, executing a stock option at a price of $2.49 per share. Additionally, he disposed of shares in multiple transactions, with sales occurring at prices ranging from $87.27 to $94.91 per share. Following these transactions, Borgeson holds a total of 304,500 shares.
These transactions may impact various stakeholders, including current and potential investors, as they provide insight into the financial strategies employed by the company's leadership. The reported sales were conducted under a 10b5-1 trading plan, which allows executives to sell shares in a predetermined manner to avoid accusations of insider trading.
The filing does not specify what actions will follow these transactions, leaving stakeholders to interpret the implications of Borgeson's stock activity.